Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reliant Technologies Inc.

Division of Valeant Pharmaceuticals International Inc.

Latest From Research Triangle Institute

Addiction Therapies Inc.

Positing substance addiction as a memory disease, Addiction Therapies Inc. seeks to address both its chemical and behavioral components. Initially targeting nicotine, alcohol and cocaine addiction, ATI will combine novel therapeutics drugs with proprietary dosing strategies in a platform designed to actively engage addicts in their own recovery.

Pharma U.

Savvy venture capitalists, biotech firms, and pharmaceutical companies have long recognized universities as technology troves of untapped value. In the last year or so, universities have developed a heightened perception of their own value--and are increasingly willing to exploit it through creative dealmaking. A look at the previous six months of licenses and research agreements signed between universities and pharmaceutical companies.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Laser
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Valeant Pharmaceuticals International Inc.
  • Senior Management
  • Eric B Stang, Pres. & CEO
    Andrew Galligan, CFO
    Keith J Sullivan, VP, Sales
  • Contact Info
  • Reliant Technologies Inc.
    Phone: (888) 437-2935
    464 Ellis St.
    Mountain View, CA 94043